Hee-Je Kim, M.D.
Korean J Hematol 2010; 45(2): 79-80Ji Eun Cho
Korean J Hematol 2010; 45(2): 81-83Thad T. Ghim, M.D.
Korean J Hematol 2010; 45(2): 84-87Soo-Young Bae, and Je-Jung Lee
Korean J Hematol 2010; 45(2): 88Jae-Hee Lee, and Jung-Sook Ha
Korean J Hematol 2010; 45(2): 89Robert T. Means Jr
Korean J Hematol 2010; 45(2): 90-94Je-Hwan Lee, Sung-Soo Yoon, Chul Won Jung, Jung-Hee Lee, Dae-Young Kim, Young-Shin Lee, Sung Cheol Yun, Inho Kim, Seonyang Park, Byoung Kook Kim, Kihyun Kim, Jin Seok Ahn, and Kyoo-Hyung Lee
Korean J Hematol 2010; 45(2): 95-101Ji Hyun Lee, Jimin Choi, Kyung A Kwon, Suee Lee, Sung Yong Oh, Hyuk-Chan Kwon, Hyo-Jin Kim, Jin Yeong Han, and Sung-Hyun Kim
Korean J Hematol 2010; 45(2): 102-108Jeong A Park, Thad Ghim, Keun Wook Bae, Kyung Nam Koh, Ho Joon Im, and Jong Jin Seo
Korean J Hematol 2010; 45(2): 109-114
Treatment overview and outcomes for patients with marrow-relapse ALL.
|@|~(^,^)~|@|Event-free survival rates and overall survival rates of patients with marrow-relapse ALL. Event-free survival rates differed due to the achievement of second remission (